| |
| |
|
| Insider
Information: |
Nader Francois |
| Relationship: |
Director |
| City: |
Salt Lake City |
| State: |
UT |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
27,356 |
|
|
Indirect Shares
|
386,932 |
|
|
| Direct
Value |
$1,206,384 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
414,288 |
|
|
| Total
Value |
$1,206,384 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
NPS Pharmaceuticals Inc |
NPSP |
President, CEO and Dir... |
2015-02-21 |
0 |
|
0 |
Premium* |
|
|
Baxalta Inc |
BXLT |
Director |
2016-06-03 |
0 |
2015-07-27 |
0 |
Premium* |
|
|
Acceleron Pharma Inc |
XLRN |
Director |
2021-01-29 |
6,749 |
2017-03-02 |
0 |
Premium* |
|
|
Alexion Pharmaceuticals Inc |
ALXN |
Director |
2021-07-21 |
0 |
2017-11-29 |
0 |
Premium* |
|
|
Prevail Therapeutics Inc. |
PRVL |
Director |
2019-06-24 |
0 |
2021-01-22 |
0 |
Premium* |
|
|
Tourmaline Bio |
TRML |
Director |
2022-07-25 |
0 |
2022-07-25 |
386,932 |
Premium* |
|
|
Moderna, Inc. |
MRNA |
Director |
2022-05-10 |
20,607 |
2022-04-28 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TRML |
Tourmaline Bio |
Director |
– • – |
2022-07-25 |
4 |
A |
$0.00 |
$0 |
I/I |
138,500 |
386,932 |
0 |
- |
|
| TRML |
Tourmaline Bio |
Director |
– • – |
2022-07-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(138,500) |
0 |
0 |
- |
|
| TRML |
Tourmaline Bio |
Director |
– • – |
2022-07-21 |
4/A |
D |
$0.00 |
$0 |
I/I |
(248,432) |
147,255 |
0 |
- |
|
| TRML |
Tourmaline Bio |
Director |
– • – |
2022-07-21 |
4 |
B |
$3.72 |
$135,780 |
D/D |
36,500 |
138,500 |
2.39 |
- |
|
| TRML |
Tourmaline Bio |
Director |
– • – |
2022-07-21 |
4 |
A |
$0.00 |
$0 |
I/I |
248,432 |
248,432 |
0 |
- |
|
| TRML |
Tourmaline Bio |
Director |
– • – |
2022-07-21 |
4 |
D |
$0.00 |
$0 |
I/I |
(248,432) |
87,735 |
0 |
- |
|
| TRML |
Tourmaline Bio |
Director |
– • – |
2022-07-20 |
4 |
B |
$3.62 |
$188,240 |
D/D |
52,000 |
102,000 |
2.39 |
- |
|
| TRML |
Tourmaline Bio |
Director |
– • – |
2022-07-19 |
4 |
B |
$3.52 |
$176,000 |
D/D |
50,000 |
50,000 |
2.39 |
- |
|
| MRNA |
Moderna, Inc. |
Director |
• • – |
2022-05-10 |
4 |
OE |
$18.87 |
$435,897 |
D/D |
23,100 |
23,803 |
0 |
- |
|
| MRNA |
Moderna, Inc. |
Director |
• • – |
2022-05-10 |
4 |
AS |
$136.10 |
$434,976 |
D/D |
(3,196) |
20,607 |
0 |
- |
|
| MRNA |
Moderna, Inc. |
Director |
• • – |
2022-04-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
703 |
703 |
0 |
- |
|
| TRML |
Tourmaline Bio |
Director |
– • – |
2021-12-15 |
4 |
GD |
$0.00 |
$0 |
I/I |
59,520 |
336,167 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Director |
– • – |
2021-07-21 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,921) |
0 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Director |
– • – |
2021-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,635 |
13,921 |
0 |
- |
|
| TRML |
Tourmaline Bio |
Director |
– • – |
2021-05-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
395,687 |
|
- |
|
| XLRN |
Acceleron Pharma Inc |
Director |
– • – |
2021-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
1,622 |
6,749 |
0 |
- |
|
| PRVL |
Prevail Therapeutics Inc. |
Director |
– • – |
2021-01-22 |
4 |
D |
$0.00 |
$0 |
I/I |
(23,747) |
0 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Director |
– • – |
2020-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,409 |
11,286 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
Director |
– • – |
2020-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,377 |
5,127 |
0 |
- |
|
| PRVL |
Prevail Therapeutics Inc. |
Director |
– • – |
2019-06-24 |
4 |
A |
$0.00 |
$0 |
I/I |
23,747 |
23,747 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Director |
– • – |
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,726 |
6,877 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
Director |
– • – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
1,250 |
3,750 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Director |
– • – |
2018-05-09 |
4 |
A |
$0.00 |
$0 |
D/D |
2,174 |
4,151 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
Director |
– • – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,250 |
2,500 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Director |
– • – |
2017-11-29 |
4 |
A |
$0.00 |
$0 |
D/D |
1,977 |
1,977 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
